MARKER THERAPEUTICS (MRKR)
(Delayed Data from NSDQ)
$2.66 USD
0.00 (0.00%)
Updated Sep 25, 2024 11:24 AM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Brokerage Reports
MARKER THERAPEUTICS, INC. [MRKR]
Reports for Purchase
Showing records 1 - 20 ( 55 total )
Company: MARKER THERAPEUTICS, INC.
Industry: Medical - Biomedical and Genetics
Company: MARKER THERAPEUTICS, INC.
Industry: Medical - Biomedical and Genetics
Company: MARKER THERAPEUTICS, INC.
Industry: Medical - Biomedical and Genetics
Company: MARKER THERAPEUTICS, INC.
Industry: Medical - Biomedical and Genetics
2Q22: Efforts Underway to Expand Pipeline. Lead Program AML Data in 3Q.
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: MARKER THERAPEUTICS, INC.
Industry: Medical - Biomedical and Genetics
Company: MARKER THERAPEUTICS, INC.
Industry: Medical - Biomedical and Genetics
Company: MARKER THERAPEUTICS, INC.
Industry: Medical - Biomedical and Genetics
Company: MARKER THERAPEUTICS, INC.
Industry: Medical - Biomedical and Genetics
4Q21: Active Disease Acute Myeloid Leukemia Readout in 2Q22
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: MARKER THERAPEUTICS, INC.
Industry: Medical - Biomedical and Genetics
Company: MARKER THERAPEUTICS, INC.
Industry: Medical - Biomedical and Genetics
Company: MARKER THERAPEUTICS, INC.
Industry: Medical - Biomedical and Genetics
Early AML Data Inconclusive. Rating Neutral. PT $1.
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: MARKER THERAPEUTICS, INC.
Industry: Medical - Biomedical and Genetics
Looking into 1Q22, Cash Balance, & Price Target Changes
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: MARKER THERAPEUTICS, INC.
Industry: Medical - Biomedical and Genetics
Biotechnology-Looking into 1Q22, Cash Balance, & Price Target Changes
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: MARKER THERAPEUTICS, INC.
Industry: Medical - Biomedical and Genetics
Biotechnology- Catalysts from Our Coverage Universe: YE2021 and Beyond
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: MARKER THERAPEUTICS, INC.
Industry: Medical - Biomedical and Genetics
Company: MARKER THERAPEUTICS, INC.
Industry: Medical - Biomedical and Genetics
Company: MARKER THERAPEUTICS, INC.
Industry: Medical - Biomedical and Genetics
Company: MARKER THERAPEUTICS, INC.
Industry: Medical - Biomedical and Genetics
Company: MARKER THERAPEUTICS, INC.
Industry: Medical - Biomedical and Genetics
2Q21: AML Patient Enrollment Has Begun in a Phase II Trial
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T